BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia

Conclusion: These data indicated that the halving time of BCR-ABL1 transcript was also an important prognostic factor as that of the BCR-ABL1IS. Combined observations of these two prognosis indexes are more accurate predictor for the long-term molecular response, especially for the CML-CP patients with BCR-ABL1IS >10%, and which is helpful for TKI switching as early as possible to improve patients' survival and reduce drug costs.

Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Zhimei Cai, Xiting Jia, Jie Zi, Huihui Song, Shujun Wang, Mary McGrath, Lidong Zhao, Chunhua Song, Zheng Ge Tags: Research Paper Source Type: research